2021 GRAPPA Trainee Symposium: A Summary of Oral and Poster Presentations

As part of the supplement series GRAPPA 2021, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. A.W. Armstrong, MD, MPH, Department of Dermatology, University of Southern California, Los Angeles, California, USA; R.M. Reddy, BA, Department of Dermatology, University of Southern California, Los Angeles, California, USA; K. Colaco, MSc, Women's College Research Institute, Women's College Hospital, Institute of Medical Science, Toronto, Ontario, Canada; P.A. Diaz, MD, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada; R. Kaur, PhD, Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, Ohio, USA; D. Simon, MD, Department of Internal Medicine, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg, and Universitatsklinikum Erlangen, Erlangen, Germany; M. Vecellio, PhD, Department of Rheumatology and Clinical Immunology Humanitas Research Hospital, Rozzano, Milan, Italy, and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Center, Oxford, UK; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. AWA has served as a research investigator and/or scientific advisor to AbbVie, ASLAN, Boehringer Ingelheim, BMS, EPI, Incyte, Leo Pharma, UCB, Janssen, Eli Lilly, Novartis, Ortho Dermatologics, Sun Pharma, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and ModMed; MEH has served on the National Psoriasis Foundation Board of Directors and as a research investigator and/or scientific advisor to AbbVie, Amgen, Novartis, Eli Lilly, Pfizer, UCB, and Janssen. The remaining authors declare no conflicts of interest. We have obtained ethical approval and informed consent if and when applicable. Address correspondence to Dr. A.W. Armstrong, University of Southern California, 1975 Zonal Avenue, KAM, MC 9034, Los Angeles, CA 90089, USA. Email: armstrongpublication@gmail.com. Accepted for publication December 7, 2021.

As part of the supplement series GRAPPA 2021, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. A.W. Armstrong, MD, MPH, Department of Dermatology, University of Southern California, Los Angeles, California, USA; R.M. Reddy, BA, Department of Dermatology, University of Southern California, Los Angeles, California, USA; K. Colaco, MSc, Women's College Research Institute, Women's College Hospital, Institute of Medical Science, Toronto, Ontario, Canada; P.A. Diaz, MD, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada; R. Kaur, PhD, Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, Ohio, USA; D. Simon, MD, Department of Internal Medicine, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg, and Universitatsklinikum Erlangen, Erlangen, Germany; M. Vecellio, PhD, Department of Rheumatology and Clinical Immunology Humanitas Research Hospital, Rozzano, Milan, Italy, and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Center, Oxford, UK; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. AWA has served as a research investigator and/or scientific advisor to AbbVie, ASLAN, Boehringer Ingelheim, BMS, EPI, Incyte, Leo Pharma, UCB, Janssen, Eli Lilly, Novartis, Ortho Dermatologics, Sun Pharma, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and ModMed; MEH has served on the National Psoriasis Foundation Board of Directors and as a research investigator and/or scientific advisor to AbbVie, Amgen, Novartis, Eli Lilly, Pfizer, UCB, and Janssen. The remaining authors declare no conflicts of interest. We have obtained ethical approval and informed consent if and when applicable. Address correspondence to Dr. A.W. Armstrong, University of Southern California, 1975 Zonal Avenue, KAM, MC 9034, Los Angeles, CA 90089, USA. Email: armstrongpublication@gmail.com. Accepted for publication December 7, 2021.

As part of the supplement series GRAPPA 2021, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. A.W. Armstrong, MD, MPH, Department of Dermatology, University of Southern California, Los Angeles, California, USA; R.M. Reddy, BA, Department of Dermatology, University of Southern California, Los Angeles, California, USA; K. Colaco, MSc, Women's College Research Institute, Women's College Hospital, Institute of Medical Science, Toronto, Ontario, Canada; P.A. Diaz, MD, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada; R. Kaur, PhD, Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, Ohio, USA; D. Simon, MD, Department of Internal Medicine, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg, and Universitatsklinikum Erlangen, Erlangen, Germany; M. Vecellio, PhD, Department of Rheumatology and Clinical Immunology Humanitas Research Hospital, Rozzano, Milan, Italy, and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Center, Oxford, UK; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. AWA has served as a research investigator and/or scientific advisor to AbbVie, ASLAN, Boehringer Ingelheim, BMS, EPI, Incyte, Leo Pharma, UCB, Janssen, Eli Lilly, Novartis, Ortho Dermatologics, Sun Pharma, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and ModMed; MEH has served on the National Psoriasis Foundation Board of Directors and as a research investigator and/or scientific advisor to AbbVie, Amgen, Novartis, Eli Lilly, Pfizer, UCB, and Janssen. The remaining authors declare no conflicts of interest. We have obtained ethical approval and informed consent if and when applicable. Address correspondence to Dr. A.W. Armstrong, University of Southern California, 1975 Zonal Avenue, KAM, MC 9034, Los Angeles, CA 90089, USA. Email: armstrongpublication@gmail.com. Accepted for publication December 7, 2021.

As part of the supplement series GRAPPA 2021, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. A.W. Armstrong, MD, MPH, Department of Dermatology, University of Southern California, Los Angeles, California, USA; R.M. Reddy, BA, Department of Dermatology, University of Southern California, Los Angeles, California, USA; K. Colaco, MSc, Women's College Research Institute, Women's College Hospital, Institute of Medical Science, Toronto, Ontario, Canada; P.A. Diaz, MD, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada; R. Kaur, PhD, Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, Ohio, USA; D. Simon, MD, Department of Internal Medicine, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg, and Universitatsklinikum Erlangen, Erlangen, Germany; M. Vecellio, PhD, Department of Rheumatology and Clinical Immunology Humanitas Research Hospital, Rozzano, Milan, Italy, and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Center, Oxford, UK; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. AWA has served as a research investigator and/or scientific advisor to AbbVie, ASLAN, Boehringer Ingelheim, BMS, EPI, Incyte, Leo Pharma, UCB, Janssen, Eli Lilly, Novartis, Ortho Dermatologics, Sun Pharma, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and ModMed; MEH has served on the National Psoriasis Foundation Board of Directors and as a research investigator and/or scientific advisor to AbbVie, Amgen, Novartis, Eli Lilly, Pfizer, UCB, and Janssen. The remaining authors declare no conflicts of interest. We have obtained ethical approval and informed consent if and when applicable. Address correspondence to Dr. A.W. Armstrong, University of Southern California, 1975 Zonal Avenue, KAM, MC 9034, Los Angeles, CA 90089, USA. Email: armstrongpublication@gmail.com. Accepted for publication December 7, 2021.

As part of the supplement series GRAPPA 2021, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. A.W. Armstrong, MD, MPH, Department of Dermatology, University of Southern California, Los Angeles, California, USA; R.M. Reddy, BA, Department of Dermatology, University of Southern California, Los Angeles, California, USA; K. Colaco, MSc, Women's College Research Institute, Women's College Hospital, Institute of Medical Science, Toronto, Ontario, Canada; P.A. Diaz, MD, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada; R. Kaur, PhD, Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, Ohio, USA; D. Simon, MD, Department of Internal Medicine, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg, and Universitatsklinikum Erlangen, Erlangen, Germany; M. Vecellio, PhD, Department of Rheumatology and Clinical Immunology Humanitas Research Hospital, Rozzano, Milan, Italy, and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Center, Oxford, UK; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. AWA has served as a research investigator and/or scientific advisor to AbbVie, ASLAN, Boehringer Ingelheim, BMS, EPI, Incyte, Leo Pharma, UCB, Janssen, Eli Lilly, Novartis, Ortho Dermatologics, Sun Pharma, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and ModMed; MEH has served on the National Psoriasis Foundation Board of Directors and as a research investigator and/or scientific advisor to AbbVie, Amgen, Novartis, Eli Lilly, Pfizer, UCB, and Janssen. The remaining authors declare no conflicts of interest. We have obtained ethical approval and informed consent if and when applicable. Address correspondence to Dr. A.W. Armstrong, University of Southern California, 1975 Zonal Avenue, KAM, MC 9034, Los Angeles, CA 90089, USA. Email: armstrongpublication@gmail.com. Accepted for publication December 7, 2021.

As part of the supplement series GRAPPA 2021, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. A.W. Armstrong, MD, MPH, Department of Dermatology, University of Southern California, Los Angeles, California, USA; R.M. Reddy, BA, Department of Dermatology, University of Southern California, Los Angeles, California, USA; K. Colaco, MSc, Women's College Research Institute, Women's College Hospital, Institute of Medical Science, Toronto, Ontario, Canada; P.A. Diaz, MD, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada; R. Kaur, PhD, Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, Ohio, USA; D. Simon, MD, Department of Internal Medicine, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg, and Universitatsklinikum Erlangen, Erlangen, Germany; M. Vecellio, PhD, Department of Rheumatology and Clinical Immunology Humanitas Research Hospital, Rozzano, Milan, Italy, and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Center, Oxford, UK; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. AWA has served as a research investigator and/or scientific advisor to AbbVie, ASLAN, Boehringer Ingelheim, BMS, EPI, Incyte, Leo Pharma, UCB, Janssen, Eli Lilly, Novartis, Ortho Dermatologics, Sun Pharma, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and ModMed; MEH has served on the National Psoriasis Foundation Board of Directors and as a research investigator and/or scientific advisor to AbbVie, Amgen, Novartis, Eli Lilly, Pfizer, UCB, and Janssen. The remaining authors declare no conflicts of interest. We have obtained ethical approval and informed consent if and when applicable. Address correspondence to Dr. A.W. Armstrong, University of Southern California, 1975 Zonal Avenue, KAM, MC 9034, Los Angeles, CA 90089, USA. Email: armstrongpublication@gmail.com. Accepted for publication December 7, 2021.

As part of the supplement series GRAPPA 2021, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. A.W. Armstrong, MD, MPH, Department of Dermatology, University of Southern California, Los Angeles, California, USA; R.M. Reddy, BA, Department of Dermatology, University of Southern California, Los Angeles, California, USA; K. Colaco, MSc, Women's College Research Institute, Women's College Hospital, Institute of Medical Science, Toronto, Ontario, Canada; P.A. Diaz, MD, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada; R. Kaur, PhD, Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, Ohio, USA; D. Simon, MD, Department of Internal Medicine, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg, and Universitatsklinikum Erlangen, Erlangen, Germany; M. Vecellio, PhD, Department of Rheumatology and Clinical Immunology Humanitas Research Hospital, Rozzano, Milan, Italy, and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Center, Oxford, UK; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. AWA has served as a research investigator and/or scientific advisor to AbbVie, ASLAN, Boehringer Ingelheim, BMS, EPI, Incyte, Leo Pharma, UCB, Janssen, Eli Lilly, Novartis, Ortho Dermatologics, Sun Pharma, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and ModMed; MEH has served on the National Psoriasis Foundation Board of Directors and as a research investigator and/or scientific advisor to AbbVie, Amgen, Novartis, Eli Lilly, Pfizer, UCB, and Janssen. The remaining authors declare no conflicts of interest. We have obtained ethical approval and informed consent if and when applicable. Address correspondence to Dr. A.W. Armstrong, University of Southern California, 1975 Zonal Avenue, KAM, MC 9034, Los Angeles, CA 90089, USA. Email: armstrongpublication@gmail.com. Accepted for publication December 7, 2021.

As part of the supplement series GRAPPA 2021, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. A.W. Armstrong, MD, MPH, Department of Dermatology, University of Southern California, Los Angeles, California, USA; R.M. Reddy, BA, Department of Dermatology, University of Southern California, Los Angeles, California, USA; K. Colaco, MSc, Women's College Research Institute, Women's College Hospital, Institute of Medical Science, Toronto, Ontario, Canada; P.A. Diaz, MD, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada; R. Kaur, PhD, Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, Ohio, USA; D. Simon, MD, Department of Internal Medicine, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg, and Universitatsklinikum Erlangen, Erlangen, Germany; M. Vecellio, PhD, Department of Rheumatology and Clinical Immunology Humanitas Research Hospital, Rozzano, Milan, Italy, and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Center, Oxford, UK; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. AWA has served as a research investigator and/or scientific advisor to AbbVie, ASLAN, Boehringer Ingelheim, BMS, EPI, Incyte, Leo Pharma, UCB, Janssen, Eli Lilly, Novartis, Ortho Dermatologics, Sun Pharma, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and ModMed; MEH has served on the National Psoriasis Foundation Board of Directors and as a research investigator and/or scientific advisor to AbbVie, Amgen, Novartis, Eli Lilly, Pfizer, UCB, and Janssen. The remaining authors declare no conflicts of interest. We have obtained ethical approval and informed consent if and when applicable. Address correspondence to Dr. A.W. Armstrong, University of Southern California, 1975 Zonal Avenue, KAM, MC 9034, Los Angeles, CA 90089, USA. Email: armstrongpublication@gmail.com. Accepted for publication December 7, 2021.